Background: Topical corticosteroids decrease collagen synthesis during short term treatment and can induce skin atrophy when applied over the long term. In contrast, short term tacrolimus ointment therapy does not aff...Background: Topical corticosteroids decrease collagen synthesis during short term treatment and can induce skin atrophy when applied over the long term. In contrast, short term tacrolimus ointment therapy does not affect collagen synthesis. Objectives: Our aim was to evaluate the long term effects of 0.1%tacrolimus ointment on collagen synthesis and on skin thickness in adults with moderate to severe atopic dermatitis (AD) and to compare the findings with the effects of conventional steroid based therapy. Methods: Fifty six patients with AD were treated with 0.1%tacrolimus ointment in a 1 year, open label, prospective clinical trial. Thirty six patients with AD applied conventional steroid based therapy and 27 healthy subjects were recruited as controls. The primary endpoint was the change in levels of procollagen propeptides I and III measured by radioimmunoassay between baseline and month 12. Additional endpoints included the change in skin thickness measured by ultrasound between baseline and month 12. Results: Procollagen propeptide baseline valueswere significantly lower in the group to be treated with tacrolimus ointment than in healthy controls. One year treatment with tacrolimus ointment was associated with an increase in collagen synthesis; the median increase in combined procollagen propeptide levelswas 272 μg L-1 (+140.9%, P < 0.001) and was accompanied by a significant increase in skin thickness. In three patients with visible skin atrophy, this condition ameliorated. Corticosteroidbased therapy had no significant effect on collagen synthesis; the median increase in combined procollagen propeptide levels was 11 μg L-1 (+3.9%). A significant reduction in skin thickness was demonstrated. Conclusions: Long term tacrolimus ointment therapy in patients with AD is nonatrophogenic and reverses corticosteroid induced skin atrophy.展开更多
文摘Background: Topical corticosteroids decrease collagen synthesis during short term treatment and can induce skin atrophy when applied over the long term. In contrast, short term tacrolimus ointment therapy does not affect collagen synthesis. Objectives: Our aim was to evaluate the long term effects of 0.1%tacrolimus ointment on collagen synthesis and on skin thickness in adults with moderate to severe atopic dermatitis (AD) and to compare the findings with the effects of conventional steroid based therapy. Methods: Fifty six patients with AD were treated with 0.1%tacrolimus ointment in a 1 year, open label, prospective clinical trial. Thirty six patients with AD applied conventional steroid based therapy and 27 healthy subjects were recruited as controls. The primary endpoint was the change in levels of procollagen propeptides I and III measured by radioimmunoassay between baseline and month 12. Additional endpoints included the change in skin thickness measured by ultrasound between baseline and month 12. Results: Procollagen propeptide baseline valueswere significantly lower in the group to be treated with tacrolimus ointment than in healthy controls. One year treatment with tacrolimus ointment was associated with an increase in collagen synthesis; the median increase in combined procollagen propeptide levelswas 272 μg L-1 (+140.9%, P < 0.001) and was accompanied by a significant increase in skin thickness. In three patients with visible skin atrophy, this condition ameliorated. Corticosteroidbased therapy had no significant effect on collagen synthesis; the median increase in combined procollagen propeptide levels was 11 μg L-1 (+3.9%). A significant reduction in skin thickness was demonstrated. Conclusions: Long term tacrolimus ointment therapy in patients with AD is nonatrophogenic and reverses corticosteroid induced skin atrophy.
